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Background: Continuous understanding of the epidemiology of drug resistant TB, especially
for multidrug/extensively drug resistant TB (MDR/XDR-TB) is essential to develop the
appropriate strategies for preventing its epidemic. The present study aimed to investigate
the longitudinal trend of the rates and dynamic change of MDR/XDR M.Tuberculosis and its
transmission pattern to adjust the TB control activities in eastern rural China.
Methods: The data presented here spanned 8 years and was derived from three population-
based studies of drug-resistant TB in two eastern rural counties: DQ and GY in terms of
socio-demographic characteristics of drug-resistant cases, as well as the microbiological
and molecular features of their infected M.Tuberculosis strains in eastern rural China.
Results: Of the 990 smear-positive patients within the studied period, 413 (41.7%) cases
showed resistance to any of the detected first- (INH, RIF and EMB) and second-line (OFL,
LEV, KAN, AMK, and CAP) anti-TB drugs: 89 with MDR (9.0%). Of these MDR-TB isolates,
34 cases (38.2%) showed resistance to any of the second-line anti-TB drugs: 25 (28.1%) with
resistance either to FQs or second-line injective drugs (Pre-XDR) and 9 (10.1%) showed
simultaneous resistance to the two categories (XDR). Molecular analysis of pncA gene
revealed 185 M.Tuberculosis cases contained the mutation associated with PZA resistance,
with a significantly higher proportion in MDR compared with the others (35% vs. 16.8%,
p = 0.04). For the longitudinal perspective, MDR-TB (from 9.1% to 14.5%, p = 0.001), Pre-
XDR-TB (from 2.5% to 4.5%, p = 0.01) and XDR-TB (from 0.9% to 3.6%, p = 0.04) exhibited
an upward trend, while there was a significant decreasing change in the proportion of
totally first-line drug sensitivity (p = 0.047). Non-linear regression analysis showed that
MDR-TB, Pre-XDR-TB and XDR-TB increased significantly over the study period with a
double time of 4.8 year (95% CI: 3.69–5.92), 3.2 year (95% CI: 2.16–5.94) and 3.3 year (95%
CI: 1.099–8.32). Being clustered, sputum smear result and previously treated history were
factors increasing the trending of M/XDR-TB. The MIRU24 loci genotyping revealed the 21
clusters involving 48 (28.4%) drug-resistant cases in DQ and 28 clusters involving 59
(32.1%) drug-resistant cases in GY. Of these clusters, 11 were related to MDR/XDR-TB and
8 of these clustered genotypes were observed more than 5 years of the study period.
Conclusion: These results show that active transmission of MDR/XDR-TB is taking place and
that the increasing trend in the observed rate of MDR/XDR-TB tends to be due to the
variation in the distribution of patients with different socio-demographic features anda.
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clinical isolates of M.Tuberculosis is needed to identify M/XDR-TB, especially in patients
who have a history of TB and have received prior anti-TB treatment.
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